These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 35900009)

  • 1. Inactivated COVID-19 vaccines: durability of Covaxin/BBV152 induced immunity against variants of concern.
    Kumar NP; Banurekha VV; Kumar CPG; Nancy A; Padmapriyadarsini C; Shankar S; Hanna LE; Murhekar M; Devi KRU; Babu S
    J Travel Med; 2022 Sep; 29(6):. PubMed ID: 35900009
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Elucidating the Immune Response to SARS-CoV-2: Natural Infection versus Covaxin/Covishield Vaccination in a South Indian Population.
    Vanamudhu A; Devi Arumugam R; Nancy A; Selvaraj N; Moiden K; Hissar S; Ranganathan UD; Bethunaickan R; Babu S; Kumar NP
    Viruses; 2024 Jul; 16(8):. PubMed ID: 39205152
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-term evolution of humoral immune response after SARS-CoV-2 infection.
    Teyssou E; Zafilaza K; Sayon S; Marot S; Dropy M; Soulie C; Abdi B; Tubach F; Hausfater P; Marcelin AG; Boutolleau D;
    Clin Microbiol Infect; 2022 Jul; 28(7):1027.e1-1027.e4. PubMed ID: 35307573
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neutralizing antibody responses to SARS-CoV-2 Omicron variants: Post six months following two-dose & three-dose vaccination of ChAdOx1 nCoV-19 or BBV152.
    Yadav PD; Sardana V; Deshpande GR; Shinde PV; Thangaraj JWV; George LS; Sapkal GN; Patil DY; Sahay RR; Shete AM; Joshi M; Murhekar M; Godbole S; Gupta N; Prakash S; Rathore M; Ujjainiya R; Singh AP; Mishra A; Dash D; Chaudhary K; Sengupta S;
    Indian J Med Res; 2024 Feb; 159(2):223-231. PubMed ID: 38517215
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
    Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
    Front Immunol; 2021; 12():802858. PubMed ID: 35003131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sub-optimal neutralisation of omicron (B.1.1.529) variant by antibodies induced by vaccine alone or SARS-CoV-2 Infection plus vaccine (hybrid immunity) post 6-months.
    Medigeshi GR; Batra G; Murugesan DR; Thiruvengadam R; Chattopadhyay S; Das B; Gosain M; Ayushi ; Singh J; Anbalagan A; Shaman H; Pargai K; Mehdi F; Das SJ; Kahlon N; Singh S; Kshetrapal P; Wadhwa N; Pandey AK; Bhatnagar S; Garg PK
    EBioMedicine; 2022 Apr; 78():103938. PubMed ID: 35305396
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern.
    Vikkurthi R; Ansari A; Pai AR; Jha SN; Sachan S; Pandit S; Nikam B; Kalia A; Jit BP; Parray HA; Singh S; Kshetrapal P; Wadhwa N; Shrivastava T; Coshic P; Kumar S; Sharma P; Sharma N; Taneja J; Pandey AK; Sharma A; Thiruvengadam R; Grifoni A; Weiskopf D; Sette A; Bhatnagar S; Gupta N
    Nat Microbiol; 2022 Jul; 7(7):974-985. PubMed ID: 35681012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Booster dose of the inactivated COVID-19 vaccine BBV152 (Covaxin) enhances the neutralizing antibody response against Alpha, Beta, Delta and Omicron variants of concern.
    Deshpande GR; Yadav PD; Abraham P; Nyayanit DA; Sapkal GN; Shete AM; Gupta N; Vadrevu KM; Ella R; Panda S; Bhargava B
    J Travel Med; 2022 May; 29(3):. PubMed ID: 35325176
    [No Abstract]   [Full Text] [Related]  

  • 9. Immunogenicity of two COVID-19 vaccines used in India: An observational cohort study in health care workers from a tertiary care hospital.
    Arankalle V; Kulkarni-Munje A; Kulkarni R; Palkar S; Patil R; Oswal J; Lalwani S; Mishra AC
    Front Immunol; 2022; 13():928501. PubMed ID: 36211366
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants.
    Chen Y; Chen L; Yin S; Tao Y; Zhu L; Tong X; Mao M; Li M; Wan Y; Ni J; Ji X; Dong X; Li J; Huang R; Shen Y; Shen H; Bao C; Wu C
    Emerg Microbes Infect; 2022 Dec; 11(1):1524-1536. PubMed ID: 35608053
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Persistence of immunity and impact of third dose of inactivated COVID-19 vaccine against emerging variants.
    Vadrevu KM; Ganneru B; Reddy S; Jogdand H; Raju D; Sapkal G; Yadav P; Reddy P; Verma S; Singh C; Redkar SV; Gillurkar CS; Kushwaha JS; Mohapatra S; Bhate A; Rai SK; Ella R; Abraham P; Prasad S; Ella K
    Sci Rep; 2022 Jul; 12(1):12038. PubMed ID: 35835822
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inactivated vaccine Covaxin/BBV152: A systematic review.
    Ahmed TI; Rishi S; Irshad S; Aggarwal J; Happa K; Mansoor S
    Front Immunol; 2022; 13():863162. PubMed ID: 36016940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Host immune responses in aged rhesus macaques against BBV152, an inactivated SARS-CoV-2 vaccine, and cross-neutralization with beta and delta variants.
    Patil DR; Shete AM; Yadav PD; Sapkal GN; Deshpande GR; Kaushal H; Mohandas S; Fulari S; Jain R; Kumar A; Abraham P
    Front Immunol; 2023; 14():1161571. PubMed ID: 37187744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-existing antibody levels negatively correlate with antibody titers after a single dose of BBV152 vaccination.
    Das S; Singh J; Shaman H; Singh B; Anantharaj A; Sharanabasava P; Pandey R; Lodha R; Pandey AK; Medigeshi GR
    Nat Commun; 2022 Jun; 13(1):3451. PubMed ID: 35705548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal study of humoral immune responses induced by a 3-dose inactivated COVID-19 vaccine in an observational, prospective cohort.
    Tao Y; Ma M; Hu F; Li M; Geng Y; Wan Y; Mao M; Chen L; Shen Y; Zhu L; Shen H; Chen Y
    BMC Immunol; 2022 Nov; 23(1):57. PubMed ID: 36384440
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibody Avidity and Neutralizing Response against SARS-CoV-2 Omicron Variant after Infection or Vaccination.
    Dapporto F; Marchi S; Leonardi M; Piu P; Lovreglio P; Decaro N; Buonvino N; Stufano A; Lorusso E; Bombardieri E; Ruello A; Viviani S; Molesti E; Trombetta CM; Manenti A; Montomoli E
    J Immunol Res; 2022; 2022():4813199. PubMed ID: 36093434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunogenicity and immune-persistence of the CoronaVac or Covilo inactivated COVID-19 Vaccine: a 6-month population-based cohort study.
    Hua Q; Zhang H; Yao P; Xu N; Sun Y; Lu H; Xu F; Liao Y; Yang J; Mao H; Zhang Y; Zhu H; Hu X; Lv H; Jiang J
    Front Immunol; 2022; 13():939311. PubMed ID: 36032136
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Decreased and Heterogeneous Neutralizing Antibody Responses Against RBD of SARS-CoV-2 Variants After mRNA Vaccination.
    Hernández-Luis P; Aguilar R; Pelegrin-Pérez J; Ruiz-Olalla G; García-Basteiro AL; Tortajada M; Moncunill G; Dobaño C; Angulo A; Engel P
    Front Immunol; 2022; 13():816389. PubMed ID: 35464418
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omicron infection increases IgG binding to spike protein of predecessor variants.
    Mahalingam G; Periyasami Y; Arjunan P; Subaschandrabose RK; Mathivanan TV; Mathew RS; Devi RKT; Premkumar PS; Muliyil J; Srivastava A; Moorthy M; Marepally S
    J Med Virol; 2023 Feb; 95(2):e28419. PubMed ID: 36546401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Preclinical evaluation of safety and immunogenicity of a primary series intranasal COVID-19 vaccine candidate (BBV154) and humoral immunogenicity evaluation of a heterologous prime-boost strategy with COVAXIN (BBV152).
    Sunagar R; Prasad SD; Ella R; Vadrevu KM
    Front Immunol; 2022; 13():1063679. PubMed ID: 36569867
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.